Citigroup Initiates Coverage On Iambic Therapeutics with Buy Rating, Announces Price Target of $22

Benzinga · 4d ago
Citigroup analyst Geoff Meacham initiates coverage on Iambic Therapeutics (NASDAQ:IAM) with a Buy rating and announces Price Target of $22.